Maribavir for the Management of Cytomegalovirus in Adult Transplant Recipients: A Review of the Literature and Practical Considerations

Abstract

Objective:

To review the efficacy and safety of maribavir for management of cytomegalovirus (CMV) in solid organ transplant recipients.

Data Sources:

A literature search of PubMed and the Cochrane Controlled Trials Register (1960 to early July 2022) was performed using the following search terms: maribavir, 1263W94, and cytomegalovirus.

Study Selection and Data Extraction:

All relevant English-language studies were reviewed and considered, with a focus on phase 3 trials.

Data Synthesis:

Maribavir, an orally available benzimidazole riboside with minimal adverse effects, was originally studied for universal prophylaxis in phase 3 trials but failed to demonstrate noninferiority over placebo and oral ganciclovir. It was effective for preemptive treatment in a dose-finding Phase 2 study. Maribavir is FDA approved for treatment of refractory/resistant CMV infection based on improved response rate at 8 weeks compared with investigator-assigned therapy (IAT) when initiated at median viral loads less than approximately 10 000 IU/mL (55.7% vs 23.9%, P < 0.001). Recurrence after 8-week treatment for refractory/resistant CMV was high (maribavir 50% vs IAT 39%). Significant drug interactions exist and must be managed by a pharmacotherapy expert to prevent harm.

Relevance to Patient Care and Clinical Practice:

The addition of maribavir to the antiviral armamentarium should improve the management of refractory/resistant CMV, allowing early transition from toxic, high-cost, intravenous agents such as foscarnet and outpatient management. Optimal timing of initiation, duration, and potential alternative uses are unclear.

Conclusion:

Future studies are needed to fully elucidate the role of maribavir in the management of CMV after transplant.

Keywords

maribavir cytomegalovirus solid organ transplant

Get full access to this article

View all access options for this article.

References

Sagedal

Rollag

Hartmann

. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant. 2007;21(3):309-313. doi:10.1111/j.1399-0012.2006.00639.x.

Kotton

Kumar

Caliendo

, et al The Transplantation Society International CMV Consensus Group. The Third International consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931. doi:10.1097/TP.0000000000002191.

Razonable

Humar

. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512. doi:10.1111/ctr.13512.

Valganciclovir. Lexicomp. Published May 18, 2022. Accessed May 31, 2022. https://online.lexi.com/lco/action/doc/retrieve/docid/uofwisconsin_f/3680860?cesid=1To5IqCNfvr&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3DvalGANciclovir%26t%3Dname%26acs%3Dtrue%26acq%3Dvalgan#

Lurain

Chou

. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689-712. doi:10.1128/CMR.00009-10.

Avery

Arav-Boger

Marr

, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016;100(10):e74-e80. doi:10.1097/TP.0000000000001418.

Rolling

Jorgenson

Descourouez

Mandelbrot

Redfield

Smith

. Ganciclovir-resistant cytomegalovirus infection in abdominal solid organ transplant recipients: case series and review of the literature. Pharmacotherapy. 2017;37(10):1258-1271. doi:10.1002/phar.1987.

LIVTENCITY. Highlights of Prescribing Information. Published November 2021. Accessed May 6, 2022. https://content.takeda.com/?contenttype=pi&product=liv&language=eng&country=usa&documentnumber=1

Biron

Harvey

Chamberlain

, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46(8):2365-2372. doi:10.1128/AAC.46.8.2365-2372.2002.

10.

Williams

Hartline

Kushner

, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother. 2003;47(7):2186-2192. doi:10.1128/AAC.47.7.2186-2192.2003.

11.

Wang

Roy

Gershburg

Whitehurst

Dittmer

Pagano

. Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. J Virol. 2009;83(23):12108-12117. doi:10.1128/JVI.01575-09.

12.

Foscarnet. Lexicomp. Published May 3, 2022. Accessed May 31, 2022. https://online.lexi.com/lco/action/doc/retrieve/docid/uofwisconsin_f/3679982?cesid=3C6UyXULJIy&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dfoscarnet%26t%3Dname%26acs%3Dfalse%26acq%3Dfoscarnet#

13.

Cidofovir. Lexicomp. Published April 28, 2022. Accessed May 31, 2022. https://online.lexi.com/lco/action/doc/retrieve/docid/uofwisconsin_f/3680088?cesid=8E6hVDV0yV6&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dcidofovir%26t%3Dname%26acs%3Dtrue%26acq%3Dcido#

14.

Letermovir. Lexicomop. Published July 8, 2022. Accessed July 14, 2022. http://online.lexi.com/lco/action/doc/retrieve/docid/uofwisconsin_f/6566007?cesid=3ebVYXxg6LE&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dletermovir%26t%3Dname%26acs%3Dtrue%26acq%3Dletermo#

15.

Lalezari

Aberg

Wang

, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46(9):2969-2976. doi:10.1128/AAC.46.9.2969-2976.2002.

16.

Wang

Peck

Yin

Allanson

Wiggs

Wire

. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003;47(4):1334-1342. doi:10.1128/AAC.47.4.1334-1342.2003.

17.

Gandhi

Kotton

. Evaluating the safety of maribavir for the treatment of cytomegalovirus. Ther Clin Risk Manag. 2022;18:223-232. doi:10.2147/TCRM.S303052.

18.

Nafziger

Villano

Gaedigk

Bertino

Jr.

Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006;50(4):1130-1135. doi:10.1128/AAC.50.4.1130-1135.2006.

19.

Song

Sun

Ilic

Martin

. Summary of maribavir (SHP620) drug-drug interactions based on accumulated clinical and nonclinical data. Biol Blood Marrow Transplant. 2019;25(suppl 3):S370-S371. doi:10.1016/j.bbmt.2018.12.600.

20.

Swan

Smith

Marbury

, et al. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J Clin Pharmacol. 2007;47(2):209-217. doi:10.1177/0091270006296765.

21.

Song

Ilic

. Pharmacokinetics of maribavir in subjects with moderate hepatic impairment. ATC Meeting Abstracts. Published May 30, 2020. Accessed May 6, 2022. https://atcmeetingabstracts.com/abstract/pharmacokinetics-of-maribavir-in-subjects-with-moderate-hepatic-impairment/

22.

Goldwater

Dougherty

Schumacher

Villano

. Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults. Antimicrob Agents Chemother. 2008;52(5):1794-1798. doi:10.1128/AAC.00951-07.

23.

Pescovitz

Bloom

Pirsch

Johnson

Gelone

Villano

. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant. 2009;9(10):2324-2330. doi:10.1111/j.1600-6143.2009.02768.x.

24.

Winston

Young

Pullarkat

, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403-5410.

25.

Marty

Ljungman

Papanicolaou

, et al. Maribavir 1263-300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284-292. doi:10.1016/S1473-3099(11)70024-X. Erratum in: Lancet Infect Dis. 2011;11(5):343.

26.

Winston

Saliba

Blumberg

, et al 1263-301 Clinical Study Group. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021-3030. doi:10.1111/j.1600-6143.2012.04231.x. Erratum in: Am J Transplant. 2013;13(2):529.

27.

Maertens

Cordonnier

Jaksch

, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381(12):1136-1147. doi:10.1056/NEJMoa1714656.

28.

Avery

Marty

Strasfeld

, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489-496. doi:10.1111/j.1399-3062.2010.00550.x.

29.

Bright

Gompels

Donati

Johnston

. Successful oral treatment of ganciclovir resistant cytomegalovirus with maribavir in the context of primary immunodeficiency: first case report and review. J Clin Virol. 2017;87:12-16. doi:10.1016/j.jcv.2016.12.006.

30.

Papanicolaou

Silveira

Langston

, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255-1264. doi:10.1093/cid/ciy706.

31.

Avery

Alain

Alexander

, et al. SOLSTICE Trial Investigators Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial [published online ahead of print December 2, 2021]. Clin Infect Dis. 2021:ciab988. doi:10.1093/cid/ciab988.

32.

Highlights of prescribing information for Prevymis. Published November 2017. Accessed June 6, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209939Orig1s000,209940Orig1s000lbl.pdf

33.

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002). ClinicalTrials.gov Identifier: NCT03443869. Accessed June 7, 2022. https://clinicaltrials.gov/ct2/show/NCT03443869

34.

Ljungman

Griffiths

Paya

. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.

35.

Razonable

. Cytomegalovirus infection after liver transplantation. Current concepts and challenges. World J Gastroenterol. 2008;14:4849-4860.

36.

Khoury

Storch

Bohl

, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006;6(9):2134-2143.

37.

Karantoni

Zavras

, et al. Outcomes of refractory cytomegalovirus infection in the first year after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28(7):403.e1-403.e7. doi:10.1016/j.jtct.2022.04.016.

38.

Singh

Winston

Razonable

, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020;323(14):1378-1387. doi:10.1001/jama.2020.3138.

39.

Jorgenson

Descourouez

Kleiboeker

, et al. Cytomegalovirus antiviral stewardship in solid organ transplant recipients: a new gold standard [published online ahead of print May 23, 2022]. Transpl Infect Dis. 2022. doi:10.1111/tid.13864.

40.

Avery

Blumberg

Florescu

, et al Randomized phase 3 open-label study of Maribavir vs investigator-assigned therapy for refractory/resistant cytomegalovirus infection in transplant recipients: subgroup analyses of efficacy by organ. ATC Abstracts. Published June 7, 2021. Accessed June 1, 2022. https://atcmeetingabstracts.com/abstract/randomized-phase-3-open-label-study-of-maribavir-vs-investigator-assigned-therapy-for-refractory-resistant-cytomegalovirus-infection-in-transplant-recipients-subgroup-analyses-of-efficacy-by-organ/

41.

Strasfeld

Lee

Tatarowicz

Villano

Chou

. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis. 2010;202(1):104-108. doi:10.1086/653122.

42.

Schubert

Ehlert

Schuler-Luettmann

Gentner

Mertens

Michel

. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis. 2013;13:330. doi:10.1186/1471-2334-13-330.

43.

Chou

Song

. Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. Antiviral Res. 2019;172:104616. doi:10.1016/j.antiviral.2019.104616.

44.

Chou

Song

Crumpacker

. Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection [published online ahead of print July 29, 2020]. J Infect Dis. 2020:jiaa462. doi:10.1093/infdis/jiaa462.

45.

Santos Bravo

Plault

Sánchez Palomino

, et al. Phenotype and genotype study of novel C480F maribavir-ganciclovir cross-resistance mutation detected in hematopoietic stem cell and solid organ transplant recipients. J Infect Dis. 2021;224(6):1024-1028. doi:10.1093/infdis/jiab029.

46.

Chou

Marousek

. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother. 2006;50(10):3470-3472. doi:10.1128/AAC.00577-06.

47.

Chou

Ercolani

Derakhchan

. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral Res. 2018;157:128-133. doi:10.1016/j.antiviral.2018.07.013.

48.

Dickter

Ross

Zain

Tegtmeier

Lee

Dadwal

. Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: consideration for combination therapy. J Clin Pharm Ther. 2022;47(5):699-702. doi:10.1111/jcpt.13585.

49.

Jorgenson

Descourouez

Garg

, et al. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Transpl Infect Dis. 2021;23(4):e13693. doi:10.1111/tid.13693.

50.

Ilic

Song

Martin

. Evaluation of the effect of maribavir on cardiac repolarization in healthy participants: thorough QT/QTc study. Clin Transl Sci. 2020;13(6):1260-1270. doi:10.1111/cts.12814.

51.

Takeda Patient Support. Patient Support For Livtencity. Accessed May 6, 2022. https://www.takedapatientsupport.com/#need-assistence

52.

Drug Search. ForwardHealth. Accessed July 22, 2022. https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Provider/DrugSearch.aspx

53.

Patel

Imlay

Kaul

Stuckey

Gregg

. Ganciclovir-resistant CMV (GCV-R CMV) infection leads to poor clinical outcomes and economic burden of ganciclovir-resistant cytomegalovirus infection in lung transplant recipients. Open Forum Infect Dis. 2017;4:S730.

54.

Centers for Disease Control and Prevention. Body Measurements. Published September 10, 2021. Accessed July 24, 2022. https://www.cdc.gov/nchs/fastats/body-measurements.htm

55.

Jorgenson

Wong

Descourouez

Saddler

Smith

Mandelbrot

. Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. Transpl Infect Dis. 2021;23(4):e13617. doi:10.1111/tid.13617.

56.

Leeaphorn

Garg

Thamcharoen

Khankin

Cardarelli

Pavlakis

. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis. Am J Transplant. 2019;19(2):573-584. doi:10.1111/ajt.15183.

57.

Gardiner

Chow

Price

Nierenberg

Kent

Snydman

. Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2017;65(12):2000-2007. doi:10.1093/cid/cix696.

58.

Reischig

Prucha

Sedlackova

, et al. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients. Antivir Ther. 2011;16(8):1227-1235. doi:10.3851/IMP1879.

59.

Jorgenson

Kleiboeker

Garg

, et al. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity. Transpl Infect Dis. 2022;24(1):e13766. doi:10.1111/tid.13766.

60.

Gardiner

Chow

Brilleman

Peleg

Snydman

. The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients. Transpl Infect Dis. 2019;21(6):e13189. doi:10.1111/tid.13189.